4
Changes in Ownership
CRISPR Therapeutics AG Filed Acc 0001193125-26-007875
Chief Financial Officer sold 29,700 shares at an average $60.16 ($1,786,636)
- Chief Financial Officer acquired 29,700 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
Prasad Raju · Chief Financial Officer
Table I: Non-derivative
5 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2026-01-06 | Exercise or conversion : show line 1 in the form 10b5-1 | +23,361 | $45.15 | $1,054,749 | 30,128 | D |
| 2026-01-06 | Exercise or conversion : show line 2 in the form 10b5-1 | +6,339 | $44.31 | $280,881 | 36,467 | D |
| 2026-01-06 | Sale : show line 3 in the form 10b5-1 | −18,933 | $60.18 | $1,139,386 | 17,534 | D |
| 2026-01-06 | Sale : show line 4 in the form 10b5-1 | −5,004 | $60.00 | $300,240 | 12,530 | D |
| 2026-01-06 | Sale : show line 5 in the form 10b5-1 | −5,763 | $60.21 | $347,010 | 6,767 | D |
| Open-market sales · 29,700 sh · avg $60.16 · $1,786,636 | ||||||
Table II: Derivative
2 lines| Date | Transaction | Shares | Owned after | D/I |
|---|---|---|---|---|
| 2026-01-06 | Exercise or conversion : show line 6 in the form 10b5-1 Stock Option (Right to Buy) | −23,361 | 76,639 | D |
| 2026-01-06 | Exercise or conversion : show line 7 in the form 10b5-1 Stock Option (Right to Buy) | −6,339 | 7,493 | D |
Loading xslF345X05/ownership.xml…